Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

NCT02072512 ·Status: UNKNOWN ·Phase: PHASE2

Fulvestrant in Metastatic Breast Cancer

NCT03591549 ·Status: UNKNOWN ·Phase: PHASE4

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

NCT00183963 ·Status: TERMINATED ·Phase: PHASE2

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01142401 ·Status: COMPLETED ·Phase: PHASE2

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

NCT01597388 ·Status: COMPLETED ·Phase: PHASE1

Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

NCT00093002 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-

NCT05140655 ·Status: UNKNOWN

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

NCT02447328 ·Status: COMPLETED ·Phase: PHASE4

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

NCT02137083 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

NCT05076695 ·Status: UNKNOWN ·Phase: PHASE2

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

NCT03202862 ·Status: UNKNOWN ·Phase: PHASE2

Faslodex Registry: Fulvestrant in Current Clinical Practice

NCT00735215 ·Status: COMPLETED

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT01344031 ·Status: COMPLETED ·Phase: PHASE1

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

NCT01339442 ·Status: COMPLETED ·Phase: PHASE1

A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant

NCT02540330 ·Status: TERMINATED ·Phase: PHASE2

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NCT02684032 ·Status: COMPLETED ·Phase: PHASE1

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

NCT03633331 ·Status: COMPLETED ·Phase: PHASE2

BRaziLian outcomE for metAStatic breasT Cancer

NCT05559528 ·Status: UNKNOWN

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

NCT02340221 ·Status: TERMINATED ·Phase: PHASE3

Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

NCT02955394 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Trastuzumab Deruxtecan in Advanced Breast Cancer

NCT07180264 ·Status: RECRUITING

"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

NCT02530424 ·Status: COMPLETED ·Phase: PHASE2

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

NCT00432172 ·Status: COMPLETED ·Phase: PHASE2

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

NCT06231693 ·Status: TERMINATED